<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016573</url>
  </required_header>
  <id_info>
    <org_study_id>070/12</org_study_id>
    <secondary_id>1034397</secondary_id>
    <nct_id>NCT02016573</nct_id>
  </id_info>
  <brief_title>Renal Denervation for Uncontrolled Hypertension</brief_title>
  <acronym>RDNP-2012-02</acronym>
  <official_title>Renal Denervation for Uncontrolled Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study investigating the safety and usefulness of the Renal Denervation Procedure in
      reducing high blood pressure in people whose blood pressure is not adequately controlled
      despite already being treated with 2 blood pressure lowering drugs. This study is designed to
      compare the effects renal denervation to a usual care group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 4 randomised control trial of renal denervation for the treatment of
      uncontrolled hypertension.

      Previous studies have shown that the renal denervation procedure is safe and effective in
      reducing blood pressure.

      A total of 100 participants with uncontrolled blood pressure, treated with two blood pressure
      lowering medications will be recruited into the study. Patients will be assigned to one of
      two groups. Participants in Group 1 will be assigned to undergo the renal denervation
      procedure. Participants in group 2 will undergo usual care, receiving additional
      antihypertensive medication in an attempt to reach blood pressure targets.

      The duration of this study is 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled into study and protocol has been superseded
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure control</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>percentage of patients who achieve BP target at 6 months post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of drugs required to reach target blood pressure</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>number of drugs required to reach target blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to achieve blood pressure target</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>time to achieve blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in sympathetic nerve activity</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>changes in muscle sympathetic nerve activity (MSNA), renal and whole body Noradrenaline (NA) spillover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular function</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in left Ventricular ejection fraction, diastolic filling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in Quality of life as assessed be relevant questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Biochemistry</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of arterial stiffness</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in markers of arterial stiffness as assessed by Augmentation Index (AI) and Pulse Wave Velocity (PWV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular structure</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in left ventricular mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Biochemistry</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants randomised to undergo the renal denervation procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal Denervation Catheter</description>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <other_name>Symplicity Renal Denervation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)

          -  concurrent treatment with 2 anti-hypertensive drugs

        Exclusion Criteria:

          -  renal artery anatomy ineligible for treatment

          -  eGFR &lt;15mL/min/1.73m2 (using MDRD formula)

          -  individual has had myocardial infarction, unstable angina or cerebrovascular accident
             within 6 months of screening visit

          -  female participants of child bearing potential must have negative pregnancy test prior
             to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus P Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart &amp; Diabetes Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <keyword>blood pressure</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>target organ damage</keyword>
  <keyword>sympathetic activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

